Our companion diagnostic is a simple test that measures levels of RSK2 in metastatic HR+/HER- tumors. Once receiving confirmation that your tumor has high levels of RSK2, you will be eligible to enroll in Dauntless-1, which is our Phase 2 clinical trial. Dauntless-1 is designed to test whether a study drug (PMD-026) in combination with fulvestrant has an effect on tumors in patients with breast cancer. This trial will further test safety and efficacy.

Our Test

Details About Our Trial

Once patients have progressed past the standard of care, which includes CDK4/6 and Aromatase inhibitors, they may have the option to enroll in our trial.